Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31480801 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL31480709 | 0.81 | CCR6 (0.41) | HDAC1ALDH1A1MAPK1L3MBTL1MAPT | |
| SCHEMBL31480720 | 0.80 | ALDH1A1 (0.40) | ALDH1A1MAPK1L3MBTL1TSHRLMNA | |
| SCHEMBL31480820 | 0.79 | CCR6 (0.41) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL31480731 | 0.79 | CYP2D6 (0.42) | HDAC1ALDH1A1MAPK1L3MBTL1F13A1 | |
| SCHEMBL31480765 | 0.79 | HDAC1 (0.45) | HDAC1ALDH1A1MAPK1F13A1TGM2 | |
| SCHEMBL31480704 | 0.78 | L3MBTL1 (0.42) | HDAC1ALDH1A1L3MBTL1F13A1TGM2 | |
| SCHEMBL25275744 | 0.78 | ALDH1A1 (0.40) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL31480883 | 0.77 | CETP (0.40) | HDAC1ALDH1A1MAPK1F13A1TGM2 | |
| SCHEMBL31480884 | 0.76 | CCR6 (0.42) | ALDH1A1MAPK1L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | HDAC1 371/4885ALDH1A1 684/4885MAPK1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.